Tisagenlecleucel can help 2 groups of people who have cancer that either comes back or isn’t helped by the usual treatments (relapsed or refractory cancer):
- Young people, from infants to young adults aged 26 years, who have acute lymphoblastic leukemia (ALL)
- Adults, aged 18 and older, who have non-Hodgkin lymphoma (NHL)
These relapsed or refractory cancers are very serious. Before CAR-T therapy was developed, most people died.
This study showed that after getting tisagenlecleucel, cancer cells could not be found in:
- 85% of people with ALL
- 40% of people with NHL
These results were similar to those of the first clinical trial for tisagenlecleucel.
This study also showed similar rates of unwanted effects. Though temporary, these effects can be serious.
About half of people had cytokine release syndrome (CRS), which causes fevers and organ problems.
And roughly 1 in 4 people had brain problems, ranging from confusion to seizures.
These problems usually get better over time.